Abiraterone acetate plus low-dose prednisone has a favorable safety profile in metastatic castration-resistant prostate cancer progressing after docetaxel-based chemotherapy: Results from COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study Meeting Abstract
| Authors: | Fizazi, K.; de Bono, J.; Haqq, C.; Logothetis, C. C.; Jones, R. J.; Chi, K.; Kheoh, T.; Molina, A.; Scher, H. |
| Abstract Title: | Abiraterone acetate plus low-dose prednisone has a favorable safety profile in metastatic castration-resistant prostate cancer progressing after docetaxel-based chemotherapy: Results from COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study |
| Meeting Title: | 26th Annual Congress of the European Association of Urology |
| Journal Title: | European Urology, Supplements |
| Volume: | 10 |
| Issue: | 2 |
| Meeting Dates: | 2011 Mar 18-22 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 1569-9056 |
| Publisher: | European Association of Urology |
| Date Published: | 2011-03-01 |
| Start Page: | 338 |
| Language: | English |
| ACCESSION: | WOS:000288715302325 |
| PROVIDER: | wos |
| DOI: | 10.1016/S1569-9056(11)61076-2 |
| Notes: | --- - Meeting Abstract: 1098 - "Source: Wos" |
